Restrictive Versus Liberal Thresholds for Red Blood Cell Transfusion in ExtraCorporeal Membrane Oxygenation - the TREC Study

Status: Recruiting
Location: See all (12) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Objective: The primary objective of this trial is to study in a prospective randomized comparison whether a restrictive RBC transfusions strategy is non-inferior compared to a liberal strategy in patients on ECMO with respect to 90-day mortality. Study design: Prospective multi-center randomized controlled non-inferiority trial. Study population: Patients, 18 years or older, receiving ECMO. Intervention: Restrictive RBC transfusion threshold: in case the Hb transfusion trigger of 7.0 g/dL (4.3 mmol/L) is reached, 1 RBC unit at a time will be transfused. The aimed Hb target range of the restrictive/intervention group will be 7.1 - 9.0 g/dL (4.3 - 5.6 mmol/L). Liberal RBC transfusion threshold: in case the Hb transfusion trigger of 9.0 g/dL (5.6 mmol/L) is reached, 1 RBC unit at a time will be transfused. Target range of the liberal group is defined as Hb 9.1 - 11.0 g/dL Main study parameters/endpoints: The primary outcome parameter is 90-day all-cause mortality. Secondary outcomes include: 1) proportion of patients on ECMO exposed to allogeneic RBC transfusion; 2) RBC volume infused per patient during ECMO; 3) reasons for RBC transfusion other than Hb triggers; 4) transfusion reactions; 5) time on ECMO; 6) length of hospital- and ICU-stay; 7) in-ICU morbidity; 8) quality of life (QoL), iMTA Medical Consumption Questionnaire (iMCQ) and Productivity Cost Questionnaire (iPCQ) at 3, 6, 9, and 12 months; 9) costs related to a) transfusion, b) hospital admission and c) transfusion-related sequelae.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient is aged 18 years or older;

• Is receiving ECMO;

• (Deferred) informed consent.

Locations
Other Locations
Belgium
Hôpital Erasme Brussels
RECRUITING
Brussels
CHU Charleroi
RECRUITING
Charleroi
KU Leuven, medical IC
RECRUITING
Leuven
KU Leuven, surgical IC
RECRUITING
Leuven
Netherlands
Amsterdam UMC, location AMC
RECRUITING
Amsterdam
Medisch Spectrum Twente (MST)
RECRUITING
Enschede
Universitair Medisch Centrum Groningen (UMCG)
RECRUITING
Groningen
Leids Universitair Medisch Centrum (LUMC)
NOT_YET_RECRUITING
Leiden
Maastricht Universitair Medisch Centrum+ (MUMC+)
RECRUITING
Maastricht
St. Antonius Ziekenhuis
RECRUITING
Nieuwegein
Erasmus MC
NOT_YET_RECRUITING
Rotterdam
Sweden
Karolinska Universtiy Hospital
NOT_YET_RECRUITING
Stockholm
Contact Information
Primary
Alexander P.J. Vlaar, PhD
a.p.vlaar@amsterdamumc.nl
020 566 9111
Backup
Stefan F. van Wonderen, MD
s.vanwonderen@amsterdamumc.nl
020 566 9111
Time Frame
Start Date: 2024-11-26
Estimated Completion Date: 2029-10-01
Participants
Target number of participants: 526
Treatments
Active_comparator: Restrictive strategy
The restrictive strategy will consist of a transfusion Hb threshold of 7.0 g/dL, with a target Hb range of 7.1 - 9.0 g/dL. These thresholds are based on previous non-inferior trials in the patient populations in which VV ECMO (comparable to sepsis) and VA ECMO (cardiac surgery, acute myocardial infarction) are often applied.
Active_comparator: Liberal strategy
The liberal strategy will consist of a transfusion Hb threshold of 9.0 g/dL, with a target Hb range of 9.1 - 11.0 g/dL. These Hb thresholds are based on thresholds that are currently used in ECMO.
Related Therapeutic Areas
Sponsors
Leads: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators: ZonMw: The Netherlands Organisation for Health Research and Development

This content was sourced from clinicaltrials.gov